CN114269382B - 用于治疗副蛋白血症性神经病的方法的补体系统的拮抗剂 - Google Patents

用于治疗副蛋白血症性神经病的方法的补体系统的拮抗剂 Download PDF

Info

Publication number
CN114269382B
CN114269382B CN202080037596.6A CN202080037596A CN114269382B CN 114269382 B CN114269382 B CN 114269382B CN 202080037596 A CN202080037596 A CN 202080037596A CN 114269382 B CN114269382 B CN 114269382B
Authority
CN
China
Prior art keywords
complement
domain
antibody
cells
mmn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080037596.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN114269382A (zh
Inventor
克里斯托弗·布朗什托
凯文·巴丁
埃里克·哈克
卡伦·西伦斯
英格·万德瓦勒
卢多·万德尔波尔
彼得·博罗什
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agence Co ltd
Original Assignee
ArgenX SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ArgenX SE filed Critical ArgenX SE
Priority to CN202410047987.6A priority Critical patent/CN118021970A/zh
Publication of CN114269382A publication Critical patent/CN114269382A/zh
Application granted granted Critical
Publication of CN114269382B publication Critical patent/CN114269382B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6408—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21043—Classical-complement-pathway C3/C5 convertase (3.4.21.43)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080037596.6A 2019-05-21 2020-05-21 用于治疗副蛋白血症性神经病的方法的补体系统的拮抗剂 Active CN114269382B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410047987.6A CN118021970A (zh) 2019-05-21 2020-05-21 用于治疗副蛋白血症性神经病的方法的补体系统的拮抗剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1907153.9A GB2584105B (en) 2019-05-21 2019-05-21 Methods of treating neuropathy
GB1907153.9 2019-05-21
PCT/EP2020/064234 WO2020234432A1 (en) 2019-05-21 2020-05-21 Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410047987.6A Division CN118021970A (zh) 2019-05-21 2020-05-21 用于治疗副蛋白血症性神经病的方法的补体系统的拮抗剂

Publications (2)

Publication Number Publication Date
CN114269382A CN114269382A (zh) 2022-04-01
CN114269382B true CN114269382B (zh) 2024-02-23

Family

ID=67385155

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080037596.6A Active CN114269382B (zh) 2019-05-21 2020-05-21 用于治疗副蛋白血症性神经病的方法的补体系统的拮抗剂
CN202410047987.6A Pending CN118021970A (zh) 2019-05-21 2020-05-21 用于治疗副蛋白血症性神经病的方法的补体系统的拮抗剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410047987.6A Pending CN118021970A (zh) 2019-05-21 2020-05-21 用于治疗副蛋白血症性神经病的方法的补体系统的拮抗剂

Country Status (22)

Country Link
US (1) US20250066460A1 (https=)
EP (2) EP4570316A3 (https=)
JP (3) JP7607590B2 (https=)
KR (1) KR20220010505A (https=)
CN (2) CN114269382B (https=)
AU (1) AU2020279543A1 (https=)
BR (1) BR112021023198A2 (https=)
CA (1) CA3138401A1 (https=)
DK (1) DK3972643T3 (https=)
EA (1) EA202193189A1 (https=)
ES (1) ES3035736T3 (https=)
FI (1) FI3972643T3 (https=)
GB (1) GB2584105B (https=)
HU (1) HUE072743T2 (https=)
IL (1) IL288010A (https=)
LT (1) LT3972643T (https=)
MA (1) MA71752A (https=)
MX (2) MX2021014170A (https=)
PL (1) PL3972643T3 (https=)
PT (1) PT3972643T (https=)
SG (1) SG11202112232YA (https=)
WO (1) WO2020234432A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020121282A1 (en) * 2018-12-13 2020-06-18 Argenx Bvba Antibodies to human complement factor c2b and methods of use
EP4059949A1 (en) * 2021-03-18 2022-09-21 Affilogic Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders
EP4308590A1 (en) 2021-03-18 2024-01-24 Affilogic Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders
EP4308591A4 (en) * 2021-03-18 2025-04-02 Affilogic POLYPEPTIDES FOR COMPLEMENT INHIBITION
CN117597353A (zh) * 2021-03-18 2024-02-23 艾菲洛之克公司 抗因子c3的sac7d变体及其治疗补体介导疾患的医疗用途
JP2025503545A (ja) * 2021-12-30 2025-02-04 アネクソン，インコーポレーテッド ハンチントン病を治療するための組成物及び方法
CA3259060A1 (en) * 2022-07-14 2024-01-18 argenx BV DOSAGE REGIMEN FOR THE TREATMENT OF MULTIFOCAL MOTOR NEUROPATHY (MMN)
CN121443634A (zh) * 2023-03-07 2026-01-30 克利夫兰诊所基金会 人补体成分2结合分子
WO2025146509A1 (en) * 2024-01-05 2025-07-10 argenx BV Methods of treating multifocal motor neuropathy (mmn)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007293239A1 (en) * 2006-09-08 2008-03-13 Volution Immuno Pharmaceuticals Sa Method of treating peripheral nerve disorders
CN102949719A (zh) * 2012-04-28 2013-03-06 上海市徐汇区中心医院 静脉注射免疫球蛋白抑制霍乱毒素和半乳糖凝集素-1结合到神经节苷脂gm1
CN105492461A (zh) * 2013-05-23 2016-04-13 布罗泰欧制药有限公司 结合人类补体因子c2的结合分子及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US8501705B2 (en) * 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
CA2662480C (en) * 2006-09-05 2016-11-08 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
LT3028716T (lt) * 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
LT2894165T (lt) * 2008-11-10 2023-03-10 Alexion Pharmaceuticals, Inc. Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui
WO2010056399A1 (en) * 2008-11-17 2010-05-20 Incode Biopharmaceutics, Inc. Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors
CN110229216B (zh) * 2011-09-07 2023-06-16 宾夕法尼亚州大学理事会 具有改善的药代动力学性质的坎普他汀类肽
WO2014096958A1 (en) * 2012-11-02 2014-06-26 Academisch Medisch Centrum Inosine monophosphate and salts thereof for use in the treatment of complement-related disorders
EP2996722A4 (en) * 2013-05-15 2017-01-11 Annexon, Inc. Methods of treatment for guillain-barre syndrome
SG10201804960RA (en) * 2013-12-12 2018-07-30 Alnylam Pharmaceuticals Inc Complement component irna compositions and methods of use thereof
HUE070383T2 (hu) * 2014-11-05 2025-06-28 Annexon Inc Humanizált C1Q anti-komplement faktor antitestek és alkalmazásaik
US11091591B2 (en) * 2015-09-16 2021-08-17 Universität Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
WO2017091719A1 (en) * 2015-11-24 2017-06-01 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof
EP3454902A4 (en) * 2016-05-10 2019-10-09 Annexon, Inc. ANTI-COMPLEMENT FACTOR C4 / C4B ANTIBODIES AND USES THEREOF
CA3055781A1 (en) * 2017-03-14 2018-09-20 Bioverativ Usa Inc. Methods for treating complement-mediated diseases and disorders
AU2018360697A1 (en) * 2017-11-01 2020-05-14 Alnylam Pharmaceuticals, Inc. Complement component C3 iRNA compositions and methods of use thereof
WO2020121282A1 (en) * 2018-12-13 2020-06-18 Argenx Bvba Antibodies to human complement factor c2b and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007293239A1 (en) * 2006-09-08 2008-03-13 Volution Immuno Pharmaceuticals Sa Method of treating peripheral nerve disorders
CN102949719A (zh) * 2012-04-28 2013-03-06 上海市徐汇区中心医院 静脉注射免疫球蛋白抑制霍乱毒素和半乳糖凝集素-1结合到神经节苷脂gm1
CN105492461A (zh) * 2013-05-23 2016-04-13 布罗泰欧制药有限公司 结合人类补体因子c2的结合分子及其应用

Also Published As

Publication number Publication date
US20250066460A1 (en) 2025-02-27
SG11202112232YA (en) 2021-12-30
DK3972643T3 (da) 2025-07-21
IL288010A (en) 2022-01-01
HUE072743T2 (hu) 2025-12-28
JP2025038109A (ja) 2025-03-18
NZ781789A (en) 2025-03-28
JP2025041724A (ja) 2025-03-26
EP4570316A3 (en) 2025-08-13
ES3035736T3 (en) 2025-09-08
GB2584105A (en) 2020-11-25
BR112021023198A2 (pt) 2022-01-04
PT3972643T (pt) 2025-07-15
MA71752A (fr) 2025-05-30
CN118021970A (zh) 2024-05-14
EP3972643A1 (en) 2022-03-30
FI3972643T3 (fi) 2025-07-16
JP7607590B2 (ja) 2024-12-27
LT3972643T (lt) 2025-07-10
AU2020279543A1 (en) 2021-11-25
CN114269382A (zh) 2022-04-01
PL3972643T3 (pl) 2025-09-08
CA3138401A1 (en) 2020-11-26
EA202193189A1 (ru) 2022-03-11
GB2584105B (en) 2023-08-02
JP2022533705A (ja) 2022-07-25
EP4570316A2 (en) 2025-06-18
KR20220010505A (ko) 2022-01-25
EP3972643B1 (en) 2025-05-14
MX2025014486A (es) 2026-01-07
MX2021014170A (es) 2022-01-04
WO2020234432A1 (en) 2020-11-26
GB201907153D0 (en) 2019-07-03

Similar Documents

Publication Publication Date Title
CN114269382B (zh) 用于治疗副蛋白血症性神经病的方法的补体系统的拮抗剂
US20250002567A1 (en) Anti-complement factor c1q fab fragments and uses thereof
CN104220454B (zh) 人源化的嵌合抗因子Bb抗体及其用途
CN117024583A (zh) 抗N3pGlu淀粉状蛋白β肽抗体及其用途
JP7499760B2 (ja) 脳損傷を治療するための組成物及び方法
AU2017264690A1 (en) Compositions and methods for treating spinal muscular atrophy
AU2017299579A1 (en) Compositions and methods for treating frontotemporal dementia
CN115996752B (zh) 用于治疗癫痫的组合物和方法
HK40063067A (en) Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies
HK40105187A (zh) 用於治疗副蛋白血症性神经病的方法的补体系统的拮抗剂
HK40063067B (zh) 用於治疗副蛋白血症性神经病的方法的补体系统的拮抗剂
EA048122B1 (ru) Способы лечения нейропатий
HK40062141A (en) Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies
HK40062141B (en) Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies
CA3006092C (en) Anti-complement factor c1q fab fragments and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40063067

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: Ghent Zvinalde, Belgium

Patentee after: Agence Co.,Ltd.

Country or region after: Belgium

Address before: Ghent Zvinalde, Belgium

Patentee before: ARGEN-X B.V.

Country or region before: Belgium

CP03 Change of name, title or address